Parameswaran Neetha, Samuvel Devadoss John, Kumar Ramesh, Thatai Sangeeta, Bal Vineeta, Rath Satyajit, George Anna
National Institute of Immunology, Aruna Asaf Ali Road, New Delhi 110067, India.
Infect Immun. 2004 Jul;72(7):3803-11. doi: 10.1128/IAI.72.7.3803-3811.2004.
The physiological ramifications of oral tolerance remain poorly understood. We report here that mice fed ovalbumin (OVA) exhibit oral tolerance to subsequent systemic immunization with OVA in adjuvant, and yet they clear systemic infection with a recombinant OVA-expressing strain of Salmonella enterica serovar Typhimurium better than unfed mice do. Mice fed a sonicated extract of S. enterica serovar Typhimurium are also protected against systemic bacterial challenge, and the protection is Th1 mediated, as feeding enhances clearance in interleukin-4-null (IL-4(-/-)) and IL-10(-/-) mice but not in gamma interferon-null (IFN-gamma(-/-)) mice. When T-cell priming in vivo is tracked temporally in T-cell receptor-transgenic mice fed a single low dose of OVA, CD4 T-cell activation and expansion are restricted largely to mucosal lymphoid organs. However, T cells from spleens and peripheral lymph nodes of fed mice proliferate and secrete IFN-gamma when restimulated with OVA in vitro, indicating the presence of primed T cells in systemic tissues following oral exposure to antigen. Nonetheless, oral tolerance can be observed in the fed mice as reduced recall responses following subsequent systemic immunization with OVA in adjuvant. Soluble OVA administered systemically has similar effects in vivo, and the "tolerance" seen in both cases can be partially reversed if the initial priming is made more immunogenic. Together, the results indicate that antigen exposure under poor adjuvantic conditions, whether oral or systemic, may lead to T-cell commitment to effector rather than proliferative capabilities, necessitating a reassessment of therapeutic modalities for induction of oral tolerance in allergic or autoimmune states.
口服耐受的生理影响仍知之甚少。我们在此报告,喂食卵清蛋白(OVA)的小鼠对随后用佐剂中的OVA进行全身免疫表现出口服耐受,但它们清除表达重组OVA的鼠伤寒沙门氏菌血清型鼠伤寒菌株的全身感染的能力比未喂食的小鼠更强。喂食鼠伤寒沙门氏菌血清型鼠伤寒菌株超声提取物的小鼠也受到保护,免受全身细菌攻击,且这种保护是由Th1介导的,因为喂食可增强白细胞介素-4基因敲除(IL-4(-/-))和白细胞介素-10基因敲除(IL-10(-/-))小鼠的清除能力,但对γ干扰素基因敲除(IFN-γ(-/-))小鼠则无此作用。当在喂食单剂量低剂量OVA的T细胞受体转基因小鼠中随时间追踪体内T细胞启动时,CD4 T细胞的激活和扩增主要局限于黏膜淋巴器官。然而,喂食小鼠脾脏和外周淋巴结中的T细胞在体外再次用OVA刺激时会增殖并分泌IFN-γ,这表明口服接触抗原后全身组织中存在已启动的T细胞。尽管如此,喂食小鼠仍可观察到口服耐受,表现为随后用佐剂中的OVA进行全身免疫时回忆反应降低。全身给予可溶性OVA在体内有类似作用,并且如果初始启动更具免疫原性,两种情况下出现的“耐受”都可部分逆转。总之,结果表明,在不良佐剂条件下的抗原暴露,无论是口服还是全身暴露,都可能导致T细胞致力于效应功能而非增殖能力,这需要重新评估在过敏性或自身免疫性状态下诱导口服耐受的治疗方式。